| 2026-10-01 | Results | Results posted: Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens | Trial register ClinicalTrials.gov |
| 2026-09-17 | Trial | New trial registered: Exploring the Combination of Intracalvariosseous and Intravenous Antibiotics for Moderate to Severe Bacterial Meningitis | Trial register ClinicalTrials.gov |
| 2026-09-14 | Trial | New trial registered: Differentiating True Nephrotoxicity From Pseudo-nephrotoxicity: A Prospective Comparative Study of Vancomycin Plus Piperacillin-Tazobactam vs. Merop | Trial register ClinicalTrials.gov |
| 2026-09-09 | Recall | FDA recall, Class II: Baxter Healthcare Corporation. CGMP Deviations | Regulator FDA enforcement reports |
| 2026-09-09 | Recall | FDA recall, Class II: Baxter Healthcare Corporation. CGMP Deviations | Regulator FDA enforcement reports |
| 2026-09-09 | Results | Results posted: Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus | Trial register ClinicalTrials.gov |
| 2026-08-25 | Trial | New trial registered: Efficacy of Mixture of Vancomycin With Xenograft for Immediate Implant Placement in Chronic Infected Socket | Trial register ClinicalTrials.gov |
| 2026-08-19 | Label | FDA label revised: TYZAVAN (NDA211962) | Regulator FDA drug label register |
| 2026-08-17 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA210729) | Regulator FDA drug label register |
| 2026-08-17 | Label | FDA label revised: vancomycin hydrochloride (ANDA218130) | Regulator FDA drug label register |
| 2026-08-10 | Trial | New trial registered: A Clinical Trial Evaluating Fecal Microbiota Transplantation (FMT) in Adolescents With ADHD | Trial register ClinicalTrials.gov |
| 2026-08-05 | Label | FDA label revised: vancomycin hydrochloride (ANDA210729) | Regulator FDA drug label register |
| 2026-07-31 | Label | FDA label revised: Vancomycin Hydrochloride (NDA210274) | Regulator FDA drug label register |
| 2026-07-30 | Label | FDA label revised: vancomycin hydrochloride (ANDA065490) | Regulator FDA drug label register |
| 2026-07-22 | Results | Results posted: Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA | Trial register ClinicalTrials.gov |
| 2026-07-20 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA063076) | Regulator FDA drug label register |
| 2026-07-14 | Label | FDA label revised: Vancomycin Hydrochloride for Oral Solution (NDA208910) | Regulator FDA drug label register |
| 2026-07-14 | Label | FDA label revised: FIRVANQ (NDA208910) | Regulator FDA drug label register |
| 2026-07-08 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA215197) | Regulator FDA drug label register |
| 2026-06-26 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA210729) | Regulator FDA drug label register |
| 2026-06-26 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA210729) | Regulator FDA drug label register |
| 2026-06-22 | Trial | New trial registered: Implementation of Vancomycin Powder Application in the Emergency Department for Open Fractures | Trial register ClinicalTrials.gov |
| 2026-06-16 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA061667) | Regulator FDA drug label register |
| 2026-06-12 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA061667) | Regulator FDA drug label register |
| 2026-06-12 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA061667) | Regulator FDA drug label register |
| 2026-06-12 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA065401) | Regulator FDA drug label register |
| 2026-06-12 | Trial | New trial registered: Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis | Trial register ClinicalTrials.gov |
| 2026-06-09 | Label | FDA label revised: VANCOMYCIN HYDROCHLORIDE (NDA050671) | Regulator FDA drug label register |
| 2026-06-08 | Trial | New trial registered: To Evaluate the Impact of MRSA Nasal Screen Implementation. | Trial register ClinicalTrials.gov |
| 2026-06-08 | Trial | New trial registered: IO Vancomycin Administration in TKA | Trial register ClinicalTrials.gov |
| 2026-05-27 | Trial | New trial registered: Intraosseous Antibiotics for Osseointegration | Trial register ClinicalTrials.gov |
| 2026-05-26 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA061667) | Regulator FDA drug label register |
| 2026-05-26 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA061667) | Regulator FDA drug label register |
| 2026-05-26 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA061667) | Regulator FDA drug label register |
| 2026-05-26 | Trial | New trial registered: Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions | Trial register ClinicalTrials.gov |
| 2026-05-15 | Label | FDA label revised: VANCOMYCIN HYDROCHLORIDE (ANDA212332) | Regulator FDA drug label register |
| 2026-05-15 | Label | FDA label revised: VANCOMYCIN HYDROCHLORIDE (ANDA215821) | Regulator FDA drug label register |
| 2026-05-13 | Trial | New trial registered: Fecal Microbiota Transplantation in Parkinson's Disease. | Trial register ClinicalTrials.gov |
| 2026-05-07 | Results | Results posted: Effect of Bed Bathing Methods on VRE Colonization in ICU Patients | Trial register ClinicalTrials.gov |
| 2026-05-05 | Results | Results posted: Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) | Trial register ClinicalTrials.gov |
| 2026-04-29 | Trial | New trial registered: The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS) | Trial register ClinicalTrials.gov |
| 2026-04-23 | Trial | New trial registered: Efficacy and Cost-Effectiveness of Topical Vancomycin Powder in Preventing Pediatric Ventriculoperitoneal Shunt Infections Across Different Etiologi | Trial register ClinicalTrials.gov |
| 2026-04-22 | Results | Results posted: Vancomycin for Primary Sclerosing Cholangitis | Trial register ClinicalTrials.gov |
| 2026-04-21 | Results | Results posted: Abbreviated Protocol for Two-Stage Exchange | Trial register ClinicalTrials.gov |
| 2026-04-15 | Recall | FDA recall, Class II: Fagron Compounding Services. Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port | Regulator FDA enforcement reports |
| 2026-04-15 | Recall | FDA recall, Class II: Fagron Compounding Services. Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port | Regulator FDA enforcement reports |
| 2026-04-15 | Recall | FDA recall, Class II: Fagron Compounding Services. Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port | Regulator FDA enforcement reports |
| 2026-04-15 | Results | Results posted: Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients | Trial register ClinicalTrials.gov |
| 2026-04-13 | Trial | New trial registered: Human Clinical Trial to Evaluate the Decolonization Efficacy of BM111 Against Carbapenem-Resistant Enterobacteriaceae (CRE) and Vancomycin-Resistant | Trial register ClinicalTrials.gov |
| 2026-04-07 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA205694) | Regulator FDA drug label register |
| 2026-04-02 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA062912) | Regulator FDA drug label register |
| 2026-04-01 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA062912) | Regulator FDA drug label register |
| 2026-04-01 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA062912) | Regulator FDA drug label register |
| 2026-03-31 | Label | FDA label revised: VANCOMYCIN HYDROCHLORIDE (ANDA065478) | Regulator FDA drug label register |
| 2026-03-31 | Results | Results posted: Checklist to Prevent MRSA Surgical Site Infections | Trial register ClinicalTrials.gov |
| 2026-03-31 | Trial | New trial registered: First-line Surgical Versus Medical Treatment: A Retrospective Study From 2014 to 2024 in Brest (BRESTE) | Trial register ClinicalTrials.gov |
| 2026-03-27 | Trial | New trial registered: Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis | Trial register ClinicalTrials.gov |
| 2026-03-25 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA090250) | Regulator FDA drug label register |
| 2026-03-24 | Trial | New trial registered: Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure | Trial register ClinicalTrials.gov |
| 2026-03-18 | Trial | New trial registered: Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas | Trial register ClinicalTrials.gov |
| 2026-03-06 | Results | Results posted: Acute Application of Antibiotic Powder in Open Fracture Wounds | Trial register ClinicalTrials.gov |
| 2026-03-05 | Trial | New trial registered: Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Controlled Trial | Trial register ClinicalTrials.gov |
| 2026-03-02 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA061667) | Regulator FDA drug label register |
| 2026-03-02 | Label | FDA label revised: vancomycin hydrochloride (NDA050606) | Regulator FDA drug label register |
| 2026-02-27 | Results | Results posted: Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin | Trial register ClinicalTrials.gov |
| 2026-02-27 | Trial | New trial registered: Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Ost | Trial register ClinicalTrials.gov |
| 2026-02-24 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA201048) | Regulator FDA drug label register |
| 2026-02-18 | Recall | FDA recall, Class II: Fresenius Kabi Compounding, LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2026-02-18 | Recall | FDA recall, Class II: Fresenius Kabi Compounding, LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2026-02-17 | Results | Results posted: Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty | Trial register ClinicalTrials.gov |
| 2026-02-16 | Trial | New trial registered: Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia | Trial register ClinicalTrials.gov |
| 2026-02-11 | Label | FDA label revised: vancomycin hydrochloride (ANDA065490) | Regulator FDA drug label register |
| 2026-01-30 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA205694) | Regulator FDA drug label register |
| 2026-01-25 | Trial | New trial registered: Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm Study | Trial register ClinicalTrials.gov |
| 2026-01-21 | Trial | New trial registered: Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia | Trial register ClinicalTrials.gov |
| 2026-01-16 | Trial | New trial registered: Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia | Trial register ClinicalTrials.gov |
| 2026-01-16 | Trial | New trial registered: Effect of Bed Bathing Methods on VRE Colonization in ICU Patients | Trial register ClinicalTrials.gov |
| 2026-01-14 | Trial | New trial registered: Intraosseous Versus Intravenous Vancomycin in Below-Knee Amputation for Ischemic Diabetic Foot | Trial register ClinicalTrials.gov |
| 2026-01-14 | Trial | New trial registered: Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis | Trial register ClinicalTrials.gov |
| 2026-01-09 | Trial | New trial registered: Vancomycin Taper to Prevent Recurrent Clostridioides Difficile | Trial register ClinicalTrials.gov |
| 2026-01-02 | Trial | New trial registered: Model-Informed Precision Dosing on Amikacin and Vancomycin Therapy in Critically Ill Children | Trial register ClinicalTrials.gov |
| 2025-12-31 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA215324) | Regulator FDA drug label register |
| 2025-12-30 | Results | Results posted: Early Antibiotics After Aspiration in ICU Patients | Trial register ClinicalTrials.gov |
| 2025-12-24 | Trial | New trial registered: Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease | Trial register ClinicalTrials.gov |
| 2025-12-23 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA218140) | Regulator FDA drug label register |
| 2025-12-22 | Label | FDA label revised: Vancocin (NDA050606) | Regulator FDA drug label register |
| 2025-12-18 | Label | FDA label revised: vancomycin hydrochloride (NDA050606) | Regulator FDA drug label register |
| 2025-12-15 | Trial | New trial registered: Vancomycin in TKAs | Trial register ClinicalTrials.gov |
| 2025-12-15 | Trial | New trial registered: IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA | Trial register ClinicalTrials.gov |
| 2025-12-05 | Trial | New trial registered: Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC) | Trial register ClinicalTrials.gov |
| 2025-12-01 | Trial | New trial registered: Local Antibiotic Concentrations With Tissue Expanders in Breast Reconstruction | Trial register ClinicalTrials.gov |
| 2025-11-28 | Label | FDA label revised: vancomycin hydrochloride (ANDA065490) | Regulator FDA drug label register |
| 2025-11-14 | Shortage | FDA shortage status to be discontinued: Vancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01) | Regulator FDA drug shortages |
| 2025-11-12 | Results | Results posted: Optimal Treatment for Recurrent Clostridium Difficile | Trial register ClinicalTrials.gov |
| 2025-11-07 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA062911) | Regulator FDA drug label register |
| 2025-10-31 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA215324) | Regulator FDA drug label register |
| 2025-10-28 | Trial | New trial registered: Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin | Trial register ClinicalTrials.gov |
| 2025-10-27 | Trial | New trial registered: A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement | Trial register ClinicalTrials.gov |
| 2025-10-27 | Trial | New trial registered: Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients | Trial register ClinicalTrials.gov |
| 2025-10-13 | Label | FDA label revised: Vancomycin Hydrochloride (ANDA063076) | Regulator FDA drug label register |